

**Screened patients  
(*n*=402)**

Non-eligible (*n*=23):

- Absence of inclusion in or completion of the early clinical treatment with trifluridine/tipiracil (*n*=21)
  - No inclusion (*n*=10)
  - No completion (*n*=11)
- Absence of histological/cytological confirmation of adenocarcinoma of colon or rectum (*n*=1)
- Age under 18 years, absence of histological/cytological confirmation of adenocarcinoma of colon or rectum, and no inclusion in the clinical experience programme for trifluridine/tipiracil (*n*=1)

**Included patients  
(*n*=379)**

Patient status at study start:

- Death (*n*=360)<sup>a</sup>
- Lost to follow-up (*n*=15)
- Alive (*n*=4)

**Supplementary Fig. 1** Summary of patient disposition. <sup>a</sup>Reasons for death included: progression (*n*=357), infection (*n*=1), pneumonia (*n*=1), and unknown (*n*=1).